|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 22, 19353-19357, May 31, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, February 15, 2002, and in revised form, March 26, 2002
Obesity is a common nutritional problem often
associated with diabetes, insulin resistance, and fatty liver (excess
fat deposition in liver). Leptin-deficient
Lepob/Lepob mice develop
obesity and those obesity-related syndromes. Increased lipogenesis in
both liver and adipose tissue of these mice has been suggested. We have
previously shown that the transcription factor sterol regulatory
element-binding protein-1 (SREBP-1) plays a crucial role in the
regulation of lipogenesis in vivo. To explore the possible
involvement of SREBP-1 in the pathogenesis of obesity and its related
syndromes, we generated mice deficient in both leptin and SREBP-1. In
doubly mutant Lepob/ob × Srebp-1 Obesity is the most common nutritional problem in the United
States, affecting ~33% of adults (1), and is often associated with
type 2 diabetes due to insulin resistance (2).
The genetically obese Lepob/Lepob
(Lepob/ob) mice develop
obesity, glucose intolerance, insulin resistance, and fatty livers
(excess fat deposition in liver) due to an inherited deficiency of the appetite-suppressing hormone, leptin (3-7). They present the most
severe obesity ever known in both rodents and humans (8), and provide a
good model of obesity and its related syndromes including insulin
resistance and fatty liver disease.
It has been reported that lipogenesis in both liver and adipose tissue
is greater in obese animals than in lean controls (5, 6). The livers of
Lepob/ob mice have an
increase in triglyceride content, probably due to the increased
lipogenesis paralleled by elevated mRNA expression and enzymatic
activity of several lipogenic enzymes such as fatty acid synthase and
ATP citrate lyase (5, 6, 9).
Sterol regulatory element-binding proteins
(SREBPs)1 are transcription
factors that belong to the basic helix-loop-helix-leucine zipper family
and regulate enzymes responsible for the synthesis of cholesterol,
fatty acids, and triglycerides (10, 11). To date, three SREBP isoforms,
SREBP-1a, -1c, and -2, have been identified and characterized. SREBP-1a
and -1c are transcribed from the same gene, each by a distinct
promoter, and the predominant SREBP-1 isoform in liver and adipose
tissue is SREBP-1c. Whereas SREBP-2 is relatively selective in
transcriptionally activating cholesterol biosynthetic genes, SREBP-1c
has a greater role in regulating fatty acid synthesis than cholesterol
synthesis (12-15). SREBP-1c was also identified as adipocyte
determination and differentiation factor-1 expressed in adipocytes and
regulated during determination and differentiation of cultured
adipocyte cell lines (16). Thus, the role of SREBP-1 in the regulation
of lipogenesis has been established (15, 17-19). Moreover, SREBP-1 now
appears to be positioned as a general mediator in the transcriptional
action of insulin (20-22).
Recently, it has been reported that both SREBP-1c mRNA and its
active nuclear protein are increased in
Lepob/ob mouse livers
(23). It is pathophysiologically intriguing and of clinical relevance
to evaluate the possible involvement of SREBP-1 in the development of
obesity and its related syndromes, since SREBP-1 could be a potential
therapeutic target in these pathological states. These considerations
prompted us to investigate the effects of SREBP-1 deletion on the
phenotype of Lepob/ob
mouse by targeted gene disruption.
Animals--
Mice deficient in SREBP-1 prepared as previously
described (24) were back-crossed six times into the C57BL/6J background and intercrossed with animals heterozygous at the leptin locus (Lep+/ob C57BL/6J; Jackson Laboratories,
Bar Harbor, ME) to generate double heterozygotes. These mice were then
interbred to produce
Lepob/ob mice whose
Srebp-1 genotypes were either wild-type
(Lepob/ob), heterozygous
(Lepob/ob × Srebp-1+/
Mice were housed in a temperature-controlled environment with a 12-h
light/dark cycle and free access to water and a standard chow diet
(Oriental MF, Oriental Yeast, Tokyo, Japan) containing 60%
carbohydrate, 13% fat, and 27% protein on a caloric basis. All
experiments were performed with 12-week-old mice. For the Lepob/ob × Srebp-1 Blood Chemistries and Liver Lipid Analyses--
Enzymatic assay
kits were used for the determination of cholesterol (Determiner TC;
cholesterol oxidase method; Kyowa Medex, Tokyo, Japan), triglycerides
(TG LH; lipoprotein lipase method; Wako Chemicals, Tokyo, Japan), and
nonesterified fatty acids (nonesterified fatty acid C; acyl-CoA oxidase
method; Wako Chemicals). Plasma glucose was measured by ANTSENSE
II (Bayer Medical, Tokyo, Japan) based on the immobilized glucose
oxidase membrane/hydrogen peroxide electrode method. Plasma insulin was
determined by the mouse insulin enzyme-linked immunosorbent assay kit
(Wako Chemicals). The content of cholesterol and triglycerides in liver
was measured as described previously (25).
RNA Isolation and Northern Blotting--
Total RNA from liver
and epididymal fat pad was isolated with Trizol reagent (Invitrogen),
and 10-µg RNA samples equally pooled from six mice of each genotype
were run on a 1% agarose gel containing formaldehyde and transferred
to a nylon membrane. The cDNA probes used were cloned as previously
described (15, 26). The probes were labeled with
[ Effects of SREBP-1 Absence on Obesity, Insulin Resistance, and
Fatty Liver in Lepob/ob Mice--
To
assess the potential effects of SREBP-1 deficiency on obesity and its
related syndromes, we intercrossed
Lepob/ob and SREBP-1-null
mice and obtained six male and six female mice deficient in both leptin
and SREBP-1 (Lepob/ob × Srebp-1
In contrast, the adiposity of
Lepob/ob mouse liver was
greatly influenced by the Srebp-1 genotype. The triglyceride
content in the livers of
Lepob/ob × Srebp-1
We concluded from these findings that the absence of SREBP-1 had no
effect on the obesity and insulin resistance of
Lepob/ob mice; however, it
did ameliorate triglyceride accumulation in liver.
Mechanisms by Which SREBP-1 Disruption Attenuates Fatty Liver in
Lepob/ob Mice--
To elucidate the
underlying mechanisms for the amelioration of fatty livers by SREBP-1
knockout in Lepob/ob mice,
we evaluated the hepatic mRNA expression of various lipogenic enzymes by Northern blot analysis (Fig.
2, Table
II). Total RNA was extracted from the
livers of six mice of each genotype in a fed state. The mRNA
abundance of SREBP-1 was reduced in
Lepob/ob × Srebp-1+/ Distinct Influence of SREBP-1 Absence on Lipogenesis in Adipose
Tissue--
While the adiposity of liver was significantly decreased
in the
Lepob/ob×Srebp-1 Effects of SREBP-1 Disruption on Markers for Insulin
Resistance--
Several adipocyte-derived genes such as tumor necrosis
factor Defective Responses of Lepob/ob Lipogenic Enzymes
in Adipose Tissue to Dietary Manipulation--
Lipogenic enzymes are
known to be markedly induced in liver and adipose tissue when animals
are refed after starvation. To further study the unexpected suppression
of lipogenic genes in Lepob/ob mouse adipose
tissue, we evaluated the refeeding response in the adipose tissue of
wild-type and Lepob/ob
mice (Fig. 5). Livers from refed
wild-type and Lepob/ob
mice displayed a similar extent of induction of all lipogenic genes
including the Srebp-1 gene. In contrast, the mRNA levels of SREBP-1 and lipogenic enzymes in the adipose tissue stayed markedly
repressed in the Lepob/ob
mice even after refeeding, whereas wild-type adipose tissue showed robust refeeding responses. These data demonstrated that the adipose tissue of Lepob/ob mice
had dysregulation of lipogenic gene expression in a fed state, whereas
the liver of Lepob/ob mice
was normal in the refeeding responses.
The current study clearly demonstrates that SREBP-1 plays a
crucial role in the development of fatty livers in
Lepob/ob mice. The
disruption of SREBP-1 caused a significant reduction in hepatic
expression of a battery of lipogenic genes and prevented fatty livers
in Lepob/ob mice,
indicating that SREBP-1 controls triglyceride accumulation in the liver
by regulating the expression levels of lipogenic enzymes. These data
are in accordance with previous reports that the overexpression of
SREBP-1 induced lipogenic enzymes and resulted in fatty livers in
several mouse models including SREBP-1a and -1c transgenic mice (12,
23, 26). It can be concluded, therefore, that SREBP-1 is a key
transcription factor that nutritionally regulates hepatic gene
expression of lipogenic enzymes and triglyceride deposition in the liver.
The observations from adipose tissue showed a remarkable contrast to
those from liver. We demonstrated from the comparison of wild-type and
Lepob/ob mice that the
mRNA levels of lipogenic enzymes and adipose tissue mass were not
correlated, suggesting that lipogenesis in adipose tissue is not the
primary cause of obesity in
Lepob/ob mice. The lower
expression of SREBP-1 and lipogenic enzymes in the
Lepob/ob mouse adipose
tissue as compared with those in wild-type has also been described
elsewhere as a part of the microarray analysis (30, 31). The difference
was more pronounced in our experiments that were performed in a refed
state (Fig. 5). It has been shown by enzymatic assay experiments that
lipogenesis in Lepob/ob
mouse adipose tissue is elevated in the early dynamic phase until 7-8
weeks of age and thereafter suppressed in the late static phase when
insulin resistance becomes evident (32, 33). In contrast, hepatic
lipogenesis in Lepob/ob
mice remains consistently higher than in wild-type animals. Therefore, lipogenesis is not likely to be important in the sustained hypertrophy of adipocytes in older
Lepob/ob mice. These
results can be explained by the fact that adipose mass is related not
only to de novo fatty acid synthesis but also to fatty acid
intake mediated through lipoprotein lipase (34). In our data, the
expression of lipoprotein lipase was not affected by SREBP-1 absence,
which could be another reason for sustained obesity in the doubly
mutant mice. Adipocyte hypertrophy can be also influenced by lipolysis
through the action of hormone-sensitive lipase (35).
We conclude from these results that the inherent suppression of SREBP-1
in Lepob/ob mouse adipose
tissue was the primary cause of the ineffectiveness of SREBP-1
disruption on obesity. Another factor that might explain the phenotypic
discrepancy between liver and adipose tissue in the
Lepob/ob × Srebp-1 We demonstrated that the adipose tissue of older
Lepob/ob mice could not
respond fully to the refeeding manipulation, whereas the livers
responded normally at least with respect to lipogenesis. Given that the
refeeding response of lipogenesis highly depends upon insulin action,
it could be said that hyperinsulinemia in Lepob/ob mice could
overcome insulin resistance to lipogenesis in the liver but could not
in the adipose tissue. This is consistent with previous reports that
the adipose tissue was more affected in an insulin-resistant state of
Lepob/ob mice than the
liver where lipid synthesis remained sensitive to insulin stimulation
throughout life (6).
It has been reported that nonalcoholic fatty liver disease is
associated with insulin resistance and hyperinsulinemia even in lean
subjects with normal glucose tolerance (36). Fatty liver disease and
insulin resistance in these patients might represent an initial stage
of the metabolic syndrome X (37, 38). In this study, we were able to
segregate fatty liver disease from insulin resistance syndromes by the
disruption of SREBP-1, an indication that excess triglyceride
accumulation in the liver is not a cause but rather the result of
insulin resistance and hyperinsulinemia.
In summary, we demonstrated that the absence of SREBP-1 attenuated
fatty livers but not obesity or insulin resistance in
Lepob/ob mice. It was
revealed that SREBP-1 plays a crucial role in the regulation of
lipogenic gene expression and triglyceride accumulation in the liver.
The ineffectiveness of SREBP-1 disruption on obesity presumably
resulted from the decreased expression of SREBP-1 in Lepob/ob mouse adipose
tissue. The data also suggested that lipogenesis is not a determinant
of obesity in Lepob/ob mice.
We are grateful to Drs. Michael S. Brown and
Joseph L. Goldstein for continuous support for the project. We
appreciate Dr. K. Komeda for support in maintaining mouse colonies.
*
This study was supported by the Promotion of Fundamental
Studies in Health Science of the Organization for Pharmaceutical Safety
and Research.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of Internal
Medicine, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan. Tel./Fax: 81-298-63-2170; E-mail: shimano-tky@umin.ac.jp.
Published, JBC Papers in Press, March 28, 2002, DOI 10.1074/jbc.M201584200
The abbreviations used are:
SREBP, sterol
regulatory element-binding protein;
PPAR
Absence of Sterol Regulatory Element-binding Protein-1 (SREBP-1)
Ameliorates Fatty Livers but Not Obesity or Insulin Resistance in
Lepob/Lepob Mice*
,
,
,
,
,
,
,
,
,
,
,
,
,
, and
Department of Internal Medicine, University
of Tokyo Graduate School of Medicine, Tokyo 113-8655 and
§ Department of Internal Medicine, Institute of Clinical
Medicine, University of Tsukuba, Ibaraki 305-8575, Japan
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice, fatty livers were
markedly attenuated, but obesity and insulin resistance remained
persistent. The mRNA levels of lipogenic enzymes such as fatty acid
synthase were proportional to triglyceride accumulation in liver. In
contrast, the mRNA abundance of SREBP-1 and lipogenic enzymes in
the adipose tissue of
Lepob/Lepob mice was profoundly
decreased despite sustained fat, which could explain why the SREBP-1
disruption had little effect on obesity. In conclusion, SREBP-1
regulation of lipogenesis is highly involved in the development of
fatty livers but does not seem to be a determinant of obesity in
Lepob/Lepob mice.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
), or homozygous
(Lepob/ob × Srebp-1
/
). The frequency for obtaining the
Lepob/ob × Srebp-1
/
progeny was as low as 1 in 43 of all pups
born, probably due to the partial embryonic lethality of SREBP-1-null
mice (24). Genotypes at the SREBP-1 locus were determined by Southern
blot analysis with BamHI digestion (24). Genotypes at the
leptin locus were determined by a PCR-based restricted fragment length polymorphism analysis; DNA fragments amplified from genomic DNA by PCR
using two primers designed on exon 2 of the leptin gene, 5'-TTTGTCCAAGATGGACCAGACT-3' and 5'-CAGGGAGCAGCTCTTGGA-3', were digested with DdeI restriction endonuclease (New England
Biolabs), which cleaves only Lepob allele-derived
products. The digested fragments were separated on a 2.5% NuSieve 3:1
agarose gel (BioWhittaker Molecular Applications, Rockland, ME). PCR
protocol was 35 cycles of 94 °C for 1 min, 60 °C for 1 min, and
72 °C for 1 min.
/
experiment, mice were refed for 12 h
following a 24-h fast prior to sacrifice in order to minimize the
variation in dietary conditions. For the fasting and refeeding study,
mice were fasted for 24 h or refed for 12 h after 24-h
starvation. All animals were sacrificed in an early phase of the light
cycle under anesthesia with diethyl ether.
-32P]dCTP using the Megaprime DNA labeling system kit
(Amersham Biosciences). The membranes were hybridized with the
radiolabeled probe in Rapid-hyb Buffer (Amersham Biosciences) at
65 °C with the exception of TNF
, for which ULTRAhyb hybridization
buffer (Ambion) was used at 42 °C. The membranes were washed in
0.1× SSC, 0.1% SDS at 65 °C. Blots were exposed to Eastman Kodak
Co. XAR-5 film and the BAS imaging plate for the BAS2000 BIO IMAGING
ANALYZER (Fuji Photo Film, Tokyo, Japan). The quantification results
obtained with the BAS2000 system were normalized to the signal
generated from 36B4 (acidic ribosomal phosphoprotein P0) mRNA.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
) in the C57BL/6J background. The
frequency for obtaining the Lepob/ob × Srebp-1
/
progeny was 3-fold lower than
expected, presumably due to the partial embryonic lethality of
SREBP-1-null mice (24). This lower proportion of
Srebp-1
/
homozygotes was similar at all
Lep genotypes, indicating that there were no lethal
interactions between the two gene deficiencies. These
Lepob/ob × Srebp-1
/
mice showed no significant
difference in body weight throughout the study period (until 12 weeks
of age) or in epididymal or parametrial fat pad weight compared with
Lepob/ob mice of either
sex (Table I). In addition, the plasma
glucose and insulin concentration of
Lepob/ob × Srebp-1
/
mice were elevated to similar
levels as those of
Lepob/ob controls,
suggesting that they had an equal level of insulin resistance
irrespective of their Srebp-1 genotype. These results indicated that SREBP-1 absence had little influence on the development of obesity and insulin resistance originating from leptin deficiency. Histological examination of the adipose tissue from
Lepob/ob × Srebp-1
/
mice revealed no change in
adipocyte hypertrophy as compared with
Lepob/ob mice (data not
shown). Plasma cholesterol levels of double homozygotes were
significantly lower than those of
Lepob/ob mice. Neither
plasma triglyceride nor nonesterified fatty acid was significantly
altered by SREBP-1 disruption.
Phenotypic characteristics of wild-type,
Lepob/ob, and
Lepob/ob × Srebp-1
/
mice
/
genotypes. NEFA, nonesterified fatty
acid.
/
mice was less than one-half that of
Lepob/ob mice, and the
Srebp-1 heterozygotes showed an intermediate value (Fig.
1b). The total liver weight of
Lepob/ob × Srebp-1
/
mice was also decreased in
comparison with Lepob/ob
controls (Fig. 1a), partly due to the diminished
triglyceride accumulation. Cholesterol content in the livers of
Lepob/ob × Srebp-1
/
mice was higher than in
Lepob/ob mice, although no
statistical significance was observed.

View larger version (16K):
[in a new window]
Fig. 1.
Effects of SREBP-1 disruption on fatty livers
in Lepob/ob
mice. Liver weight/body weight ratio (a) and liver
triglyceride content (b) in wild-type (
) C57BL/6J mice,
Lepob/ob (
),
Lepob/ob × Srebp-1+/
(
), and
Lepob/ob × Srebp-1
/
(
) mice.
Bars, S.E. for each group. p values (Student's
t test) indicate differences between
Lepob/ob
(n = 6) and
Lepob/ob × Srebp-1
/
mice (n = 6).
and was completely abolished in
Lepob/ob × Srebp-1
/
mice. The protein product of the
aberrant mRNA (denoted by asterisk in Figs. 2-4) from
the disrupted allele was previously reported to be inactive as a
transcription factor (15, 24). By Northern blot analysis, we were able
to show that the mRNA levels of various lipogenic enzymes such as
fatty acid synthase, stearoyl-CoA desaturase 1, glycerol-3-phosphate
acyltransferase, ATP citrate lyase, and spot 14 were decreased by
SREBP-1 deletion in
Lepob/ob mice livers.
Meanwhile, mRNA levels for hydroxymethylglutaryl-CoA synthase,
a key enzyme of cholesterol biosynthesis, and its controlling transcription factor, SREBP-2, were reciprocally increased in Lepob/ob × Srebp-1
/
mice. These differences were
confirmed to be statistically significant by another Northern blot
analysis quantifying gene expression levels in individual animals. The
expression levels of glucokinase and pyruvate kinase, major glycolytic
enzymes, were not altered by SREBP-1 disruption.

View larger version (48K):
[in a new window]
Fig. 2.
Effects of SREBP-1 deletion on the hepatic
gene expression in
Lepob/ob
mice. Northern blot analysis of various genes including lipogenic
and glycolytic enzymes in liver is shown. Lanes
(left to right) show wild type (WT),
Lepob/ob,
Lepob/ob × Srebp-1+/
, and
Lepob/ob × Srebp-1
/
. Total RNA (10 µg) pooled equally
from six mice was subjected to Northern blotting, followed by
hybridization with the indicated cDNA probes. FAS, fatty
acid synthase; SCD, stearoyl-CoA desaturase;
GPAT, glycerol-3-phosphate acyltransferase; ACL,
ATP citrate lyase; S14, Spot 14; HMGCoAsyn,
hydroxymethylglutaryl-CoA synthase; G6PD,
glucose-6-phosphate dehydrogenase; PK, pyruvate kinase;
GK, glucokinase. A cDNA probe for 36B4 (acidic ribosomal
phosphoprotein P0) was used to confirm equal loading. *, the aberrant
messenger RNA from the disrupted Srebp-1 allele that encodes
a truncated protein that is null for transcriptional activity. The
results of quantification by the BAS imaging plate are shown in Table
II.
Quantification of gene expression levels in livers from wild-type,
Lepob/ob,
Lepob/ob × Srebp-1+/
, and
Lepob/ob × Srebp-1
/
mice
by Northern blot analysis shown in Fig. 2
/
mice, adipose tissue mass was unchanged. To investigate the mechanism by which this occurs, we evaluated the mRNA levels of various lipogenic genes in the adipose tissue of mice from each group by
Northern blot analysis (Fig. 3, Table
III). Quite unexpectedly, the mRNA
abundance of lipogenic enzymes was markedly suppressed in adipose
tissue of Lepob/ob mice
compared with wild-type. Consistently, the mRNA level of SREBP-1
was also profoundly reduced in
Lepob/ob mouse adipose
tissue. The disruption of SREBP-1 did not further decrease the
lipogenic gene expression in adipose tissue of
Lepob/ob mice at all.

View larger version (50K):
[in a new window]
Fig. 3.
Effects of SREBP-1 absence on the mRNA
expression of various genes in adipose tissue from
Lepob/ob
mice. Northern blot analysis of various genes including lipogenic
enzymes in adipose tissue is shown. Lanes (left
to right) show wild type (WT),
Lepob/ob,
Lepob/ob × Srebp-1+/
, and
Lepob/ob × Srebp-1
/
. Total RNA (10 µg) pooled equally
from six mice was subjected to Northern blotting, followed by
hybridization with the indicated cDNA probes. FAS, fatty
acid synthase; SCD, stearoyl-CoA desaturase;
GPAT, glycerol-3-phosphate acyltransferase; ACL,
ATP citrate lyase; S14, Spot 14; HMGCoAsyn,
hydroxymethylglutaryl-CoA synthase; LPL, lipoprotein
lipase. A cDNA probe for 36B4 (acidic ribosomal phosphoprotein P0)
was used to confirm equal loading. *, the aberrant messenger RNA from
the disrupted Srebp-1 allele that encodes a truncated
protein. The results of quantification by the BAS imaging plate are
shown in Table III.
Quantification of gene expression levels in adipose tissue from
wild-type, Lepob/ob,
Lepob/ob × Srebp-1+/
, and
Lepob/ob × Srebp-1
/
mice by Northern blot analysis shown in Fig. 3
(TNF
) and peroxisome proliferator-activated receptor
(PPAR
) have been implicated to be related to insulin resistance in
adipose tissue (27), and their mRNA levels were also examined in
our study. We demonstrated that the expression of PPAR
, a nuclear receptor for thiazolidinedions, insulin-sensitizing drugs, was decreased, whereas TNF
, which has been suggested to be a causal cytokine for insulin resistance, was increased in the adipose tissue of
Lepob/ob mice compared
with wild type (Fig. 3, Table III), both of which reflect the
insulin-resistant state of
Lepob/ob mice. However,
the comparison of Lepob/ob
and Lepob/ob × Srebp-1
/
mice revealed that neither PPAR
nor TNF
was altered by the absence of SREBP-1 in the
Lepob/ob mouse adipose
tissue. These data provided further evidence that SREBP-1 is not
involved in the insulin resistance of
Lepob/ob mice. The
expression levels of lipoprotein lipase (17, 28) and leptin (29) that
had been reported to be regulated by SREBP-1 were also independent of
Srebp-1 genotype, which held true again in the
Lep+/Lep+ background
(Fig. 4).

View larger version (56K):
[in a new window]
Fig. 4.
Effects of SREBP-1 absence on mRNA levels
of leptin and lipoprotein lipase genes in the adipose tissue of lean
mice. Northern blot analysis of leptin and lipoprotein lipase
(LPL) genes in adipose tissue from wild-type (WT)
and Srebp-1
/
(KO) mice (four male
mice each) was conducted in a fasted (left two
lanes) or refed state in the
Lep+/Lep+ background.
Total RNA (10 µg) pooled equally from four mice was run in each lane.
A cDNA probe for 36B4 (acidic ribosomal phosphoprotein P0) was used
to confirm equal loading. *, the aberrant messenger RNA from the
disrupted Srebp-1 allele that encodes a truncated
protein.

View larger version (48K):
[in a new window]
Fig. 5.
Comparison of refeeding responses in
lipogenic genes between liver and adipose tissue from
Lepob/ob
mice. Northern blot analysis of lipogenic enzymes in liver
(a) and adipose tissue (b) is shown. Wild-type
(WT) and
Lepob/ob (OB)
mice (six male mice each) are compared in a fasted (left
two lanes) or refed state. Total RNA (10 µg)
pooled equally from six mice was run in each lane. FAS,
fatty acid synthase; ACL, ATP citrate lyase; S14,
Spot 14; HMGCoAsyn, hydroxymethylglutaryl-CoA synthase. A
cDNA probe for 36B4 (acidic ribosomal phosphoprotein P0) was used
to confirm equal loading.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice is the different contribution
of SREBP-1 to the regulation of lipogenesis in the two organs (15); the
disruption of SREBP-1 strongly suppressed the refeeding responses of
lipogenic enzymes in the liver, whereas their expression was less
influenced by SREBP-1 levels in the adipose tissue. It is possible that
there are other specific transcription factors that regulate
lipogenesis in adipocytes and that SREBP-1 contribution is of minor
importance in this tissue (15).
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Present address: Division of Cardiovascular Medicine,
Vanderbilt University School of Medicine, 383 Preston Research
Building, Nashville, TN 37232-6300
![]()
ABBREVIATIONS
, peroxisome
proliferator-activated receptor
;
TNF
, tumor necrosis factor
.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Kuczmarski, R. J.,
Flegal, K. M.,
Campbell, S. M.,
and Johnson, C. L.
(1994)
J. Am. Med. Assoc.
272,
205-211[Abstract]
2.
Saltiel, A. R.
(2001)
Cell
104,
517-529[CrossRef][Medline]
[Order article via Infotrieve]
3.
Ingalls, A. M.,
Dickie, M. M.,
and Snell, G. D.
(1950)
J. Hered.
41,
317-318 4.
Mayer, J.,
Bates, M. W.,
and Dickie, M. M.
(1951)
Science
113,
746-747 5.
Herberg, L.,
and Coleman, D. L.
(1977)
Metabolism
26,
59-99[CrossRef][Medline]
[Order article via Infotrieve]
6.
Bray, G. A.,
and York, D. A.
(1979)
Physiol. Rev.
59,
719-809 7.
Zhang, Y.,
Proenca, R.,
Maffei, M.,
Barone, M.,
Leopold, L.,
and Friedman, J. M.
(1994)
Nature
372,
425-432[CrossRef][Medline]
[Order article via Infotrieve]
8.
Montague, C. T.,
Farooqi, I. S.,
Whitehead, J. P.,
Soos, M. A.,
Rau, H.,
Wareham, N. J.,
Sewter, C. P.,
Digby, J. E.,
Mohammed, S. N.,
Hurst, J. A.,
Cheetham, C. H.,
Earley, A. R.,
Barnett, A. H.,
Prins, J. B.,
and O'Rahilly, S.
(1997)
Nature
387,
903-908[CrossRef][Medline]
[Order article via Infotrieve]
9.
Clandinin, M. T.,
Cheema, S.,
Pehowich, D.,
and Field, C. J.
(1996)
Lipids
31 Suppl. 2,
13-22
10.
Yokoyama, C.,
Wang, X.,
Briggs, M. R.,
Admon, A., Wu, J.,
Hua, X.,
Goldstein, J. L.,
and Brown, M. S.
(1993)
Cell
75,
187-197[CrossRef][Medline]
[Order article via Infotrieve]
11.
Brown, M. S.,
and Goldstein, J. L.
(1997)
Cell
89,
331-340[CrossRef][Medline]
[Order article via Infotrieve]
12.
Shimano, H.,
Horton, J. D.,
Shimomura, I.,
Hammer, R. E.,
Brown, M. S.,
and Goldstein, J. L.
(1997)
J. Clin. Invest.
99,
846-854[Medline]
[Order article via Infotrieve]
13.
Horton, J. D.,
Shimomura, I.,
Brown, M. S.,
Hammer, R. E.,
Goldstein, J. L.,
and Shimano, H.
(1998)
J. Clin. Invest.
101,
2331-2339[Medline]
[Order article via Infotrieve]
14.
Shimomura, I.,
Shimano, H.,
Korn, B. S.,
Bashmakov, Y.,
and Horton, J. D.
(1998)
J. Biol. Chem.
273,
35299-35306 15.
Shimano, H.,
Yahagi, N.,
Amemiya-Kudo, M.,
Hasty, A. H.,
Osuga, J.,
Tamura, Y.,
Shionoiri, F.,
Iizuka, Y.,
Ohashi, K.,
Harada, K.,
Gotoda, T.,
Ishibashi, S.,
and Yamada, N.
(1999)
J. Biol. Chem.
274,
35832-35839 16.
Tontonoz, P.,
Kim, J. B.,
Graves, R. A.,
and Spiegelman, B. M.
(1993)
Mol. Cell. Biol.
13,
4753-4759 17.
Kim, J. B.,
and Spiegelman, B. M.
(1996)
Genes Dev.
10,
1096-1107 18.
Horton, J. D.,
Bashmakov, Y.,
Shimomura, I.,
and Shimano, H.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
5987-5992 19.
Osborne, T. F.
(2000)
J. Biol. Chem.
275,
32379-32382 20.
Foretz, M.,
Guichard, C.,
Ferre, P.,
and Foufelle, F.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
12737-12742 21.
Shimomura, I.,
Bashmakov, Y.,
Ikemoto, S.,
Horton, J. D.,
Brown, M. S.,
and Goldstein, J. L.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
13656-13661 22.
Flier, J. S.,
and Hollenberg, A. N.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
14191-14192 23.
Shimomura, I.,
Bashmakov, Y.,
and Horton, J. D.
(1999)
J. Biol. Chem.
274,
30028-30032 24.
Shimano, H.,
Shimomura, I.,
Hammer, R. E.,
Herz, J.,
Goldstein, J. L.,
Brown, M. S.,
and Horton, J. D.
(1997)
J. Clin. Invest.
100,
2115-2124[Medline]
[Order article via Infotrieve]
25.
Yokode, M.,
Hammer, R. E.,
Ishibashi, S.,
Brown, M. S.,
and Goldstein, J. L.
(1990)
Science
250,
1273-1275 26.
Shimano, H.,
Horton, J. D.,
Hammer, R. E.,
Shimomura, I.,
Brown, M. S.,
and Goldstein, J. L.
(1996)
J. Clin. Invest.
98,
1575-1584[Medline]
[Order article via Infotrieve]
27.
Spiegelman, B. M.,
and Flier, J. S.
(1996)
Cell
87,
377-389[CrossRef][Medline]
[Order article via Infotrieve]
28.
Schoonjans, K.,
Gelman, L.,
Haby, C.,
Briggs, M.,
and Auwerx, J.
(2000)
J. Mol. Biol.
304,
323-334[CrossRef][Medline]
[Order article via Infotrieve]
29.
Kim, J. B.,
Sarraf, P.,
Wright, M.,
Yao, K. M.,
Mueller, E.,
Solanes, G.,
Lowell, B. B.,
and Spiegelman, B. M.
(1998)
J. Clin. Invest.
101,
1-9[Medline]
[Order article via Infotrieve]
30.
Soukas, A.,
Cohen, P.,
Socci, N. D.,
and Friedman, J. M.
(2000)
Genes Dev.
14,
963-980 31.
Nadler, S. T.,
Stoehr, J. P.,
Schueler, K. L.,
Tanimoto, G.,
Yandell, B. S.,
and Attie, A. D.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
11371-11376 32.
Hems, D. A.,
Rath, E. A.,
and Verrinder, T. R.
(1975)
Biochem. J.
150,
167-173[Medline]
[Order article via Infotrieve]
33.
Kaplan, M. L.,
and Leveille, G. A.
(1981)
Am. J. Physiol.
240,
E101-E107 34.
Weinstock, P. H.,
Levak-Frank, S.,
Hudgins, L. C.,
Radner, H.,
Friedman, J. M.,
Zechner, R.,
and Breslow, J. L.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10261-10266 35.
Osuga, J.,
Ishibashi, S.,
Oka, T.,
Yagyu, H.,
Tozawa, R.,
Fujimoto, A.,
Shionoiri, F.,
Yahagi, N.,
Kraemer, F. B.,
Tsutsumi, O.,
and Yamada, N.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
787-792 36.
Lee, J. H.,
Rhee, P. L.,
Lee, J. K.,
Lee, K. T.,
Kim, J. J.,
Koh, K. C.,
Paik, S. W.,
Rhee, J. C.,
and Choi, K. W.
(1998)
Korean J. Intern. Med.
13,
12-14[Medline]
[Order article via Infotrieve]
37.
Reaven, G. M.
(1988)
Diabetes
37,
1595-1607[Abstract]
38.
Marchesini, G.,
Brizi, M.,
Morselli-Labate, A. M.,
Bianchi, G.,
Bugianesi, E.,
McCullough, A. J.,
Forlani, G.,
and Melchionda, N.
(1999)
Am. J. Med.
107,
450-455[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
N. Anderson and J. Borlak Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis Pharmacol. Rev., September 1, 2008; 60(3): 311 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Doege, D. Grimm, A. Falcon, B. Tsang, T. A. Storm, H. Xu, A. M. Ortegon, M. Kazantzis, M. A. Kay, and A. Stahl Silencing of Hepatic Fatty Acid Transporter Protein 5 in Vivo Reverses Diet-induced Non-alcoholic Fatty Liver Disease and Improves Hyperglycemia J. Biol. Chem., August 8, 2008; 283(32): 22186 - 22192. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Qin, R. A. Anderson, and K. Adeli Tumor necrosis factor-{alpha} directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling Am J Physiol Gastrointest Liver Physiol, May 1, 2008; 294(5): G1120 - G1129. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sekiya, N. Yahagi, T. Matsuzaka, Y. Takeuchi, Y. Nakagawa, H. Takahashi, H. Okazaki, Y. Iizuka, K. Ohashi, T. Gotoda, et al. SREBP-1-independent regulation of lipogenic gene expression in adipocytes J. Lipid Res., July 1, 2007; 48(7): 1581 - 1591. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Ramsey and J. Bass Lean gene and the clock machine PNAS, June 5, 2007; 104(23): 9553 - 9554. [Full Text] [PDF] |
||||
![]() |
J. M. Schroeder-Gloeckler, S. M. Rahman, R. C. Janssen, L. Qiao, J. Shao, M. Roper, S. J. Fischer, E. Lowe, D. J. Orlicky, J. L. McManaman, et al. CCAAT/Enhancer-binding Protein beta Deletion Reduces Adiposity, Hepatic Steatosis, and Diabetes in Leprdb/db Mice J. Biol. Chem., May 25, 2007; 282(21): 15717 - 15729. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Yan, M. Lehto, L. Rasilainen, J. Metso, C. Ehnholm, S. Yla-Herttuala, M. Jauhiainen, and V. M. Olkkonen Oxysterol Binding Protein Induces Upregulation of SREBP-1c and Enhances Hepatic Lipogenesis Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1108 - 1114. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sampath, M. Miyazaki, A. Dobrzyn, and J. M. Ntambi Stearoyl-CoA Desaturase-1 Mediates the Pro-lipogenic Effects of Dietary Saturated Fat J. Biol. Chem., January 26, 2007; 282(4): 2483 - 2493. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. S. Lee, D. H. Sohn, D. Han, H.-W. Lee, R. H. Seong, and J. B. Kim Chromatin Remodeling Complex Interacts with ADD1/SREBP1c To Mediate Insulin-Dependent Regulation of Gene Expression Mol. Cell. Biol., January 15, 2007; 27(2): 438 - 452. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Loor, H. M. Dann, N. A. J. Guretzky, R. E. Everts, R. Oliveira, C. A. Green, N. B. Litherland, S. L. Rodriguez-Zas, H. A. Lewin, and J. K. Drackley Plane of nutrition prepartum alters hepatic gene expression and function in dairy cows as assessed by longitudinal transcript and metabolic profiling Physiol Genomics, January 12, 2007; 27(1): 29 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Utzschneider and S. E. Kahn The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4753 - 4761. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. P. J. Alwayn, C. Andersson, S. Lee, D. A. Arsenault, B. R. Bistrian, K. M. Gura, V. Nose, B. Zauscher, M. Moses, and M. Puder Inhibition of matrix metalloproteinases increases PPAR-{alpha} and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model Am J Physiol Gastrointest Liver Physiol, December 1, 2006; 291(6): G1011 - G1019. [Abstract] |